Expanded Access: Past, Present and Future Improvements
Additional Concepts, Closeout, EAP, Execution, Forecasting / Planning
Expanded access is a program that provides patients with investigational medicinal products (IMP) for treatment purposes. These patients are often excluded from clinical trials but could still benefit from access to the drugs, biologics or medical devices being tested. While, in concept, expanded access represents a way to help more patients receive new and developing treatments, in reality, the process is complex and often misunderstood.
Related Education Resources.
All ResourcesVideo on ACE Requirements
Topics: Pharma Industry, Strategic Planning
Video
Members
Video on eTMF Requirements provided by Steve Jacobs, Chairman at Global BioPharm Solutions.
Topics: Pharma Industry, Strategic Planning
Video
Members
PATIENT Receptivity to Direct-to-Patient Shipment in Clinical Trials - a GCSG sponsored study
Topic: Direct-to-Patient
White Paper
Members